FibroBiologics, Inc.
FBLG Nasdaq
SEC CIK 1958777
Follow FibroBiologics
Weekly email: filings, results
Net income
−$4M
+29.9% vs same quarter last year
EPS, diluted
−$0.38
+85.8% vs same quarter last year
Operating cash flow
−$2.8M
+30.6% vs same quarter last year
Operating income
−$4.1M
+19.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$18.6M |
| FY24 | −$11.2M |
| FY23 | −$16.5M |
| FY22 | −$5.1M |
| FY21 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$16.7M |
| FY24 | −$12.1M |
| FY23 | −$6.9M |
| FY22 | - |
| FY21 | - |